Michael Oestergaard
Overview
Explore the profile of Michael Oestergaard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duchamp E, Vasquez G, Firoozi N, Freestone G, Oestergaard M, Seth P, et al.
RSC Adv
. 2024 Jul;
14(33):23583-23591.
PMID: 39070250
Therapeutic oligonucleotides are chemically modified to enhance their drug-like properties - including binding affinity for target RNA. Many nucleic acid analogs that enhance RNA binding affinity constrain the furanose sugar...
2.
Chappell A, Gaus H, Berdeja A, Gupta R, Jo M, Prakash T, et al.
Nucleic Acids Res
. 2020 Mar;
48(8):4382-4395.
PMID: 32182359
Conjugation of antisense oligonucleotide (ASO) with a variety of distinct lipophilic moieties like fatty acids and cholesterol increases ASO accumulation and activity in multiple tissues. While lipid conjugation increases tissue...
3.
Yoshida S, Duong C, Oestergaard M, Fazio M, Chen C, Peralta R, et al.
Nanomedicine
. 2019 Nov;
24:102127.
PMID: 31783139
Neuroblastoma (NB) is the most common extracranial solid tumor in children. The outcomes for aggressive forms of NB remain poor. The aim of this study was to develop a new...
4.
Mazur C, Powers B, Zasadny K, Sullivan J, Dimant H, Kamme F, et al.
JCI Insight
. 2019 Oct;
4(20).
PMID: 31619586
Intrathecal (IT) delivery and pharmacology of antisense oligonucleotides (ASOs) for the CNS have been successfully developed to treat spinal muscular atrophy. However, ASO pharmacokinetic (PK) and pharmacodynamic (PD) properties remain...
5.
Satake N, Duong C, Yoshida S, Oestergaard M, Chen C, Peralta R, et al.
Mol Med
. 2016 Jul;
22:632-642.
PMID: 27455414
The exponential rise in molecular and genomic data has generated a vast array of therapeutic targets. Oligonucleotide-based technologies to down regulate these molecular targets have promising therapeutic efficacy. However, there...